Abstract
Summary
LPI (LP Information)' newest research report, the “Cancer Genomic Testing Industry Forecast” looks at past sales and reviews total world Cancer Genomic Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Genomic Testing sales for 2023 through 2029. With Cancer Genomic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Genomic Testing industry.
This Insight Report provides a comprehensive analysis of the global Cancer Genomic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Genomic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Genomic Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Genomic Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Genomic Testing.
The global Cancer Genomic Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Genomic Testing players cover Myriad Genetics, Centogene AG, Color Genomics, Quest Diagnostics, 23andMe Inc., Gene By Gene Ltd., LabCorp, Positive Bioscience and Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Genomic Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Breast Cancer Genomic Testing
Lung Cancer Genomic Testing
Blood Cancer Genomic Testing
Liver Cancer Genomic Testing
Stomach Cancer Genomic Testing
Others
Segmentation by application
Hospitals
Clinics
Diagnostic Laboratories
Academic and Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Myriad Genetics
Centogene AG
Color Genomics
Quest Diagnostics
23andMe Inc.
Gene By Gene Ltd.
LabCorp
Positive Bioscience
Bio-Rad Laboratories
Illumina, Inc.
Agilent Technologies
Thermo Fisher Scientific
This Insight Report provides a comprehensive analysis of the global Cancer Genomic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Genomic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Genomic Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Genomic Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Genomic Testing.
The global Cancer Genomic Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Genomic Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Genomic Testing players cover Myriad Genetics, Centogene AG, Color Genomics, Quest Diagnostics, 23andMe Inc., Gene By Gene Ltd., LabCorp, Positive Bioscience and Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Genomic Testing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Breast Cancer Genomic Testing
Lung Cancer Genomic Testing
Blood Cancer Genomic Testing
Liver Cancer Genomic Testing
Stomach Cancer Genomic Testing
Others
Segmentation by application
Hospitals
Clinics
Diagnostic Laboratories
Academic and Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Myriad Genetics
Centogene AG
Color Genomics
Quest Diagnostics
23andMe Inc.
Gene By Gene Ltd.
LabCorp
Positive Bioscience
Bio-Rad Laboratories
Illumina, Inc.
Agilent Technologies
Thermo Fisher Scientific
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cancer Genomic Testing Market Size 2018-2029
2.1.2 Cancer Genomic Testing Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Cancer Genomic Testing Segment by Type
2.2.1 Breast Cancer Genomic Testing
2.2.2 Lung Cancer Genomic Testing
2.2.3 Blood Cancer Genomic Testing
2.2.4 Liver Cancer Genomic Testing
2.2.5 Stomach Cancer Genomic Testing
2.2.6 Others
2.3 Cancer Genomic Testing Market Size by Type
2.3.1 Cancer Genomic Testing Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Cancer Genomic Testing Market Size Market Share by Type (2018-2023)
2.4 Cancer Genomic Testing Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Diagnostic Laboratories
2.4.4 Academic and Research Institutes
2.4.5 Others
2.5 Cancer Genomic Testing Market Size by Application
2.5.1 Cancer Genomic Testing Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Cancer Genomic Testing Market Size Market Share by Application (2018-2023)
3 Cancer Genomic Testing Market Size by Player
3.1 Cancer Genomic Testing Market Size Market Share by Players
3.1.1 Global Cancer Genomic Testing Revenue by Players (2018-2023)
3.1.2 Global Cancer Genomic Testing Revenue Market Share by Players (2018-2023)
3.2 Global Cancer Genomic Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cancer Genomic Testing by Regions
4.1 Cancer Genomic Testing Market Size by Regions (2018-2023)
4.2 Americas Cancer Genomic Testing Market Size Growth (2018-2023)
4.3 APAC Cancer Genomic Testing Market Size Growth (2018-2023)
4.4 Europe Cancer Genomic Testing Market Size Growth (2018-2023)
4.5 Middle East & Africa Cancer Genomic Testing Market Size Growth (2018-2023)
5 Americas
5.1 Americas Cancer Genomic Testing Market Size by Country (2018-2023)
5.2 Americas Cancer Genomic Testing Market Size by Type (2018-2023)
5.3 Americas Cancer Genomic Testing Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Genomic Testing Market Size by Region (2018-2023)
6.2 APAC Cancer Genomic Testing Market Size by Type (2018-2023)
6.3 APAC Cancer Genomic Testing Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cancer Genomic Testing by Country (2018-2023)
7.2 Europe Cancer Genomic Testing Market Size by Type (2018-2023)
7.3 Europe Cancer Genomic Testing Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Genomic Testing by Region (2018-2023)
8.2 Middle East & Africa Cancer Genomic Testing Market Size by Type (2018-2023)
8.3 Middle East & Africa Cancer Genomic Testing Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cancer Genomic Testing Market Forecast
10.1 Global Cancer Genomic Testing Forecast by Regions (2024-2029)
10.1.1 Global Cancer Genomic Testing Forecast by Regions (2024-2029)
10.1.2 Americas Cancer Genomic Testing Forecast
10.1.3 APAC Cancer Genomic Testing Forecast
10.1.4 Europe Cancer Genomic Testing Forecast
10.1.5 Middle East & Africa Cancer Genomic Testing Forecast
10.2 Americas Cancer Genomic Testing Forecast by Country (2024-2029)
10.2.1 United States Cancer Genomic Testing Market Forecast
10.2.2 Canada Cancer Genomic Testing Market Forecast
10.2.3 Mexico Cancer Genomic Testing Market Forecast
10.2.4 Brazil Cancer Genomic Testing Market Forecast
10.3 APAC Cancer Genomic Testing Forecast by Region (2024-2029)
10.3.1 China Cancer Genomic Testing Market Forecast
10.3.2 Japan Cancer Genomic Testing Market Forecast
10.3.3 Korea Cancer Genomic Testing Market Forecast
10.3.4 Southeast Asia Cancer Genomic Testing Market Forecast
10.3.5 India Cancer Genomic Testing Market Forecast
10.3.6 Australia Cancer Genomic Testing Market Forecast
10.4 Europe Cancer Genomic Testing Forecast by Country (2024-2029)
10.4.1 Germany Cancer Genomic Testing Market Forecast
10.4.2 France Cancer Genomic Testing Market Forecast
10.4.3 UK Cancer Genomic Testing Market Forecast
10.4.4 Italy Cancer Genomic Testing Market Forecast
10.4.5 Russia Cancer Genomic Testing Market Forecast
10.5 Middle East & Africa Cancer Genomic Testing Forecast by Region (2024-2029)
10.5.1 Egypt Cancer Genomic Testing Market Forecast
10.5.2 South Africa Cancer Genomic Testing Market Forecast
10.5.3 Israel Cancer Genomic Testing Market Forecast
10.5.4 Turkey Cancer Genomic Testing Market Forecast
10.5.5 GCC Countries Cancer Genomic Testing Market Forecast
10.6 Global Cancer Genomic Testing Forecast by Type (2024-2029)
10.7 Global Cancer Genomic Testing Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Myriad Genetics
11.1.1 Myriad Genetics Company Information
11.1.2 Myriad Genetics Cancer Genomic Testing Product Offered
11.1.3 Myriad Genetics Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Myriad Genetics Main Business Overview
11.1.5 Myriad Genetics Latest Developments
11.2 Centogene AG
11.2.1 Centogene AG Company Information
11.2.2 Centogene AG Cancer Genomic Testing Product Offered
11.2.3 Centogene AG Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Centogene AG Main Business Overview
11.2.5 Centogene AG Latest Developments
11.3 Color Genomics
11.3.1 Color Genomics Company Information
11.3.2 Color Genomics Cancer Genomic Testing Product Offered
11.3.3 Color Genomics Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Color Genomics Main Business Overview
11.3.5 Color Genomics Latest Developments
11.4 Quest Diagnostics
11.4.1 Quest Diagnostics Company Information
11.4.2 Quest Diagnostics Cancer Genomic Testing Product Offered
11.4.3 Quest Diagnostics Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Quest Diagnostics Main Business Overview
11.4.5 Quest Diagnostics Latest Developments
11.5 23andMe Inc.
11.5.1 23andMe Inc. Company Information
11.5.2 23andMe Inc. Cancer Genomic Testing Product Offered
11.5.3 23andMe Inc. Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 23andMe Inc. Main Business Overview
11.5.5 23andMe Inc. Latest Developments
11.6 Gene By Gene Ltd.
11.6.1 Gene By Gene Ltd. Company Information
11.6.2 Gene By Gene Ltd. Cancer Genomic Testing Product Offered
11.6.3 Gene By Gene Ltd. Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Gene By Gene Ltd. Main Business Overview
11.6.5 Gene By Gene Ltd. Latest Developments
11.7 LabCorp
11.7.1 LabCorp Company Information
11.7.2 LabCorp Cancer Genomic Testing Product Offered
11.7.3 LabCorp Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 LabCorp Main Business Overview
11.7.5 LabCorp Latest Developments
11.8 Positive Bioscience
11.8.1 Positive Bioscience Company Information
11.8.2 Positive Bioscience Cancer Genomic Testing Product Offered
11.8.3 Positive Bioscience Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Positive Bioscience Main Business Overview
11.8.5 Positive Bioscience Latest Developments
11.9 Bio-Rad Laboratories
11.9.1 Bio-Rad Laboratories Company Information
11.9.2 Bio-Rad Laboratories Cancer Genomic Testing Product Offered
11.9.3 Bio-Rad Laboratories Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Bio-Rad Laboratories Main Business Overview
11.9.5 Bio-Rad Laboratories Latest Developments
11.10 Illumina, Inc.
11.10.1 Illumina, Inc. Company Information
11.10.2 Illumina, Inc. Cancer Genomic Testing Product Offered
11.10.3 Illumina, Inc. Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Illumina, Inc. Main Business Overview
11.10.5 Illumina, Inc. Latest Developments
11.11 Agilent Technologies
11.11.1 Agilent Technologies Company Information
11.11.2 Agilent Technologies Cancer Genomic Testing Product Offered
11.11.3 Agilent Technologies Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Agilent Technologies Main Business Overview
11.11.5 Agilent Technologies Latest Developments
11.12 Thermo Fisher Scientific
11.12.1 Thermo Fisher Scientific Company Information
11.12.2 Thermo Fisher Scientific Cancer Genomic Testing Product Offered
11.12.3 Thermo Fisher Scientific Cancer Genomic Testing Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Thermo Fisher Scientific Main Business Overview
11.12.5 Thermo Fisher Scientific Latest Developments
12 Research Findings and Conclusion